These conditions cause breathlessness independent of diabetes medications and require specific investigation with spirometry, sleep studies, or chest imaging as clinically indicated
These include: Semaglutide ( Ozempic , Wegovy , Rybelsus ) Tirzepatide ( Mounjaro , Zepbound , compounded tirzepatide) Liraglutide (Victoza and Saxenda ) Metformin Weight loss is highly individual, so your best bet is to speak with a healthcare provider who can give you personalized advice on achieving your goals and what those goals should look like
The triple therapy of metformin, a DPP-4 inhibitor and a SGLT-2 inhibitor has a very low treatment related hypoglycaemia risk, leads to a further, almost additive reduction of glycaemic parameters, a body weight loss in the same range as with a mono- or dual therapy with a SGLT-2 inhibitor and also to the expected SGLT-2 inhibitor induced reduction of blood pressure
The dose is gradually increased, and by week four, you begin to see positive results
Common adverse reactions (occurring 5%) in TOUJEO-treated subjects during clinical trials in adult patients with type 1 diabetes mellitus and type 2 diabetes mellitus are listed in Table 1 and Table 2, respectively